Effect of combined rosuvastatin and ezetimibe on early diabetic nephropathy

Objective To observe the effect of combined rosuvastatin and ezetimibe on early diabetic nephropathy（DN）. Methods One hundred and fifty-eight DN patients with their blood sugar well controlled were randomly divided into treatment group and control group.Patients in treatment group were given ezetimibe（10mg/d） and rosuvastatin（10mg/d） with the addition of routine treatment and those in control group were given only rosuvastatin（10mg/d） to observe their fasting blood glucose,postprandial 2-h blood glucose,total cholesterol,triglycerides,low density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,creatinine,serum creatine kinase,alanine aminotransferase,aspartate aminotransferase levels,urinary protein excretion rate（UAER） and other biochemical indicators. Results The LDL-C,fasting blood glucose,postprandial 2-h blood glucose levels and UAER were significantly lower in treatment group than in control group after treatment（P＜0.05）.No significant difference was observed in transaminase and creatinine between the two groups. Conclusion Combined ezetimibe and rosuvastatin can improve the lipid profile and reduce UAER,fasting blood glucose,postprandial 2-h blood glucose levels more effectively than rosuvastatin alone with no damage to liver,kidney and muscle.